CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene–gene interactions

References

• ALEXANDRIE, A., INGELMAN SUNDBERG, M., SELDEGARD, J., TORNLING, G. and RANNUG, A. 1994, Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological types. Carcinogenesis, 15, 1785–1790.
   PubMed Web of Science ®Google Scholar
• ALEXANDROV, K., CASCORBI, I., ROJAS, M., BOUVIER, G., KRIEK, E. and BARTSC HH. 2002, CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis, 23, 1969–1977.
   PubMed Web of Science ®Google Scholar
• ANTTILA, S., HIRVONEN, A., HLTSGAFVEL-PURSIAINEN, K, KARJALALNEN, A., NTJRMINEN, T. and VAINIO, H. 2001, Combined effect of CYP1A1 and GSTM1 polymorphism on histological type of lung cancer. Pharmacogenetics, 11, 501–509.
   Google Scholar
• ANTTILA, S., LUOSTARINEN, L., HIRVONEN, A., ELOVAARA, E., KARJALAINEN, A., NURMINEN, T., HAYES, J. D., VAINIO, H. and KETTERER, B. 1995, Pulmonary expression of glutathione 5-transferase M3 in lung cancer patients: association with GSTM1 polymorphism, smoking, and asbestos exposure. Cancer Research, 55, 3305–3309.
   PubMed Web of Science ®Google Scholar
• BENHAMOU, S., LEE, W. J., ALEXANDRIE, A. K., BOFFETTA, P., BOUCHARDY, C., BUTKIEWICZ, D., BROCKMOLLER, J., CLAPPER, M. L., DALY, A., DOLZAN, V., FORD, J., GASPARI, L., HAUGEN, A., HIRVONEN, A., HUSGAFVEL-PURSIAINEN, K., INGELMAN-SUNDBERG, M., KALINA, I., KLHARA, M., KREMERS, P., LE, MARCHAND, L., LONDON, S. J., NAZAR-STEWART, V., ONON-KIHARA, M., RANNUG, A., ROMKES, M., RYBERG, D., SELDEGARD, J., SHIELDS, P., STRANGE, R. C., STUCKER, I., TO-FIGUERAS, J., BRENNAN, P. and TATOU, E. 2002, Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis, 23, 1343–1350.
   Google Scholar
• BOTJCHARDY, C., WLKMAN, H., BENHAMOU, S., HIRVONEN, A., DAYER, P. and HUSGAFVEL-PURSIAINEN, K 1997, CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in a French Caucasian population. Biomarkers, 2, 131–134.
   Google Scholar
• BRESI-OW, N. and DAY, N. 1980, Statistical Methods in Cancer Research, Vol. I: The Analysis of Case Control Studies. Science Publ. No. 32 (Lyon: IARC).
   Google Scholar
• Bu-rxrEwrcz, D., COLE, K J., PHILLIPS, D. H., HARRIS, C. C. and CHORAZY, M. 1999, GSTM1, GSTP1, CYP1A1 and CYP2D6 polymorphisms in lung cancer patients from an environmentallypolluted region of Poland: correlation with lung DNA adduct levels. European Journal of Cancer Prevention, 8, 315–323.
   Google Scholar
• DEAKIN, M., ELDER, J., HENDRICKSE, C., PECKHAM, D., BmowiN, D., PAN-riN, C., WILD, N., LEOPARD, P., BELL, D. A., JoNEs, P., DUNCAN, H., BRANNIGAN, K., ALIDERSEA, J., FRYER, A., A. and STRANGE, R. 1996, Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis, 17, 881–884.
   Google Scholar
• DOLZAN, V, RUDOLF, Z. and BRESKVAR, K 2000, Genetic polymorphism of xenobiotic metabolising enzymes in Slovenian lung cancer patients. Pflugers Arch, 439, R29–30.
   Google Scholar
• DRESLER, C. M., FRATELI-I, C., BABB, J., EVERLEY, L., EVANS, A. A. and CLAPPER, M. L. 2000, Gender differences in genetic susceptibility for lung cancer. Lung Cancer, 30, 153–160.
   Google Scholar
• FORD, J. G., Li, Y., O'SumvAN, M. M., DEMOPOULOS, R, GARTE, S., TATOU, E. and BRANDT-RAUF, P. W. 2000, Glutathione 5-transferase M1 polymorphism and lung cancer in African-Americans. Carcinogenesis, 21, 1971–1975.
   Google Scholar
• GARTE, S., BoEFErrA, P., CAPORASO, N. and VINEIS, P. 2001a, Metabolic gene allele nomenclature. Cancer Epidemiology. Biomarkers and Prevention, 10, 1305–1306.
   PubMed Web of Science ®Google Scholar
• GARTE, S., GASPARI, L., ALExANDRIE, A. K., AMBROSONE, C., AUTRUP, H., AUTRUP, J. L., BARANOVA, H., BATHUM, L., BENHAMOU, S., BOFFETTA, P., BOUCHARDY, C., BRESKVAR, K., BROCK_MOL-LER, J., CASCORBI, I., CLAPPER, M. L., Cou-rELLE, C., DALY, A., DELuOmo, M., DOLZAN, V, DRESLER, C. M., FRYER, A., HAUGEN, A., HEIN, D. VV., HILDESHEIM, A., HIRVONEN, A., HSIEH, L. L., INGELMAN-SUNDBERG, M., KALINA, I., KANG, D., KIHARA, M., KIYOHARA, C., KREMERS, P., LAZARUS, P., LE MARCHAND, L., LECHNER, M. C., VAN LIESHOUT, E. M., LONDON, S., MANNI,MAUGARD, C. M., MORITA, S., NAZAR-STEWART, V, NODA, K., ODA, Y., PARE, F. F.,PASTORELLI, R., PERSSON, I., PETERS, W. H., RANNUG, A., REBBECK, T., RISCH, A., ROELANDT, L., ROMKES, M., RYBERG, D., SALAGOVIC, J., SCHOKET, B., SEIDEGARD, J., SHIELDS, P. G., Sim, E., SLNNET, D., STRANGE, R. C., STTJCKER, I., STJGIMTJRA, H., TO-FIGTJERAS, J., VINEIS, P, YTJ,M. C. and TATOU, E. 2001b, Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiology. Biomarkers and Preventio,10, 1239–1248.
   Google Scholar
• HIRVONEN, A., HUSGAFVEL-PURSIANEN, K, ANTI-ILA, S., KARJALALNEN, A., SORSA, M. and VALNIO, H. 1992, Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics, 2, 259–263.
   Google Scholar
• HOULSTON, R. S. 2000, CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. Pharmacoge-netics, 10, 105–114.
   PubMedGoogle Scholar
• JACQUET, M., LAMBERT, V., BAUDOLTX, E., MULLER, M., KREMERS, P. and GIELEN, J. 1996, Correlation between P450 CYP1A1 inducibility, MspI genotype and lung cancer incidence. European Journal of Cancer, 32A, 1701–1706.
   PubMed Web of Science ®Google Scholar
• JOURENKOVA, N., REINLKANEN, M., BOUCHARDY, C., HUSGAFVEL-PURSIANEN, K, DAYER, P., BENHAMOU, S. and HIRVONEN, A. 1997, Effects of glutathione 5-transferase GSTM1 and GSTT1 genotypes on lung cancer risk in smokers. Pharmacogenetics, 7, 515–518.
   Google Scholar
• KELI-ERMANN, G., SHAW, C. R and Luy-rEN-KELI-ERMAN, M. 1973, Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. New England Journal of Medicine, 289, 934–937.
   PubMedGoogle Scholar
• LE MARCHAND, L., GTJO, C., BENHAMOU, S., BOUCHARDY, C., CASCORBI, I., CLAPPER, M. L., GARTE, S., HAUGEN, A., INGELMAN-STJNDBERG, M., KIHARA, M., RANNUG, A., RYBERG, D., STUCKER, I., SUGIMURA, H. and TATOU, E. 2003, Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes and Control, 14, 339–346.
   Google Scholar
• LE MARCHAND, L., SIVARAMAN, L., PIERCE, L., SEIFRIED, A., Lum, A., WILKENS, L. R and LAU, A. F. 1998, Association of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Research, 58, 4858–4863.
   PubMed Web of Science ®Google Scholar
• PASTORELLI, R, GTJANCI, M., CERRI, A., NEGRI, E., LA VECCHIA, C., FUMAGALLI, F., MEZZETTI, M., CAPPELLI, R, PANIGAIII, T., FANELLI, R. and ArEoLur, L. Impact of inherited polymorphisms in glutathione S-transferase Ml, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA and blood protein adducts of benzo(a)pyrene-diolepoxide. Cancer Epidemiology, Biomarkers and Prevention, 7, 703–709.
   Google Scholar
• RYBERG, D., SKAUG, V, HEWER, A., PurrilEs, D. H., HARRIES, L. W., ROLAND, Wolf, C., OGRELD, D., UunK, A., WI, P. and HAUGEN, A. 1997, Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis, 18, 1285–1289.
   Google Scholar
• SAARIKOSKI, S., VOHO, A., REINEKAINEN, M., ANTI-ILA, S., KARJALAINEN, A., MALAVETT I F, C., VAINIO, H., HUSGAFVEL-PURSIANEN, K and HIRVONEN, A. 1998, Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. International Journal of Cancer, 77, 516–521.
   Google Scholar
• SCHOKET, B., PAPP, G., LEVAY, K, MRACKOVA, G., KADLUBAR, F. F. and VINCZE, I. 2001, Impact of metabolic genotypes on levels of biomarkers of genotoxic exposure. Mutation Research, 482, 57–69.
   PubMed Web of Science ®Google Scholar
• SCHOKET, B., PHILLIPS, D. H., KosTic, S. and VINCZE, I. 1998, Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 MspI and GSTM1 genotypes in lung patients. Carcinogenesis, 19, 841–846.
   PubMed Web of Science ®Google Scholar
• SEIDEGARD, J. and PERO, R W. 1985, The hereditary transmission of high glutathione transferase activity towards trans-stilbene oxide in human mononuclear leukocytes. Human Genetics, 69, 66–68.
   PubMed Web of Science ®Google Scholar
• SEIDEGARD, J., VORACHEK, W. R., PERO, R W. and PEARSON, W. R 1998, Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proceedings of the National Academy of Sciences USA, 85, 7293–7297.
   Google Scholar
• STUCKER, I., JACQUET, M., DE WAZIERS, I., CENEE, S., BEATJNE, P., KREMERS, P. and HEMON, D. 2000, Relation between inducibility of CYP1A1, GSTM1 and lung cancer in a French population. Pharmacogenetics, 10, 617–627.
   PubMedGoogle Scholar
• TATOU, E. 1999, International collaborative study on genetic susceptibility to environmental carcino-gens. Cancer Epidemiology Biomarkers and Prevention, 8, 727–728.
   PubMed Web of Science ®Google Scholar
• TATOU, E., FoRD, J., TRACHMAN, J., Li, Y, DEMOPOULOS, R and GARTE, S. J. 1998, Lung cancer risk and CYP1A1 genotype in African Americans. Carcinogenesis, 19, 813–817.
   Google Scholar
• TEFRE, T., RYBERG, D., HAUGEN, A., NEBERT, D., SKAUG, V., BROGGER, A. and BORRESEN, A. HUMAN CYP1A1 (cytochrome P1450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics, 1, 20–25.
   Google Scholar
• VINEIS, P., CAPORASO, N., CUZICK, J., LANG, M., MALATS, N. and BOFFETTA, P. 1999, Genetic Susceptibility to Cancer: Metabolic Polymorphisms . Scientific Publ. No. 148 (Lyon: IARC).
   Google Scholar
• VINEIS, P., VEGLIA, F., BENHAMOU, S., BTJTKIEWICZ, D., CASCORBI, I., CLAPPER, M. L., DOLZAN, V., HAUGEN, A., HIRVONEN, A., INGELMAN-SUNDBERG, M., KIHARA, M., KIYOHARA, C., KREMERS, P., LE MARCHAND, L., OHSHIMA, S., PASTORELII, R, RANNUG, A., ROMKES, M., SCHOKET, B., SHIELDS, P., STRANGE, R. C., STTJCKER, I., STJGIMTJRA, H., GARTE, S., GASPARI, L. and TATOU, E. 2003, CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2,451 cases and 3,358 controls. International Journal of Cancer, 104, 650–657.
   Google Scholar
• WARHOLM, M., GUTHENBERG, C., MANNERVIK, B. and VON BAHR, C. 1981, Purification of a new glutathione 5-transferase (transferase mu) from human liver having high activity with benzo(al-pha)pyrene-4,5-oxide. Biochemical and Biophysical Research Communications, 98, 512–519.
   PubMed Web of Science ®Google Scholar
• WARHOLM, M., RANE, A., ALEXANDRIE, A., MONAGHAN, G. and RANNUG, A. 1995, Genotypic and phenotypic determination of polymorphic glutathione transferase Ti in a Swedish population. Pharmacogenetics, 5, 252–254.
   PubMedGoogle Scholar